Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite

AAPS Journal

Volumn 9, Issue 3, 2007, Pages

  Bonate, Peter L ^a   Beyerlein, David ^b   Crawford, Jennifer ^a   Roth, Stephanie ^a   Krumbholz, Roy ^a   Schmid, Steve ^a  

^a GENZYME CORPORATION   (United States)

^b MicroConstants   (United States)

Author keywords

Depsipeptide; ILX651; Metabolite kinetics; Prolyl oligopeptidase; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; ILX 651; PRODRUG; PROLYL ENDOPEPTIDASE INHIBITOR; TASIDOTIN; TASIDOTIN C CARBOXYLATE; CARBOXYLIC ACID; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TUMOR LEVEL; EXPERIMENTAL NEOPLASM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BLOOD; CANCER TRANSPLANTATION; HALF LIFE TIME; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOXYLIC ACIDS; HALF-LIFE; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES;

EID: 38849159510     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0903045     Document Type: Article

References (11)

1. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr Pharm Des. 1999;5:139-162.
2. Supko JG, Lynch TJ, Clark JW, et al. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol. 2000;46:319-328.
3. Ray A, Okouneva T, Manna T, et al. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite, tasidotin-C-carboxylate. Cancer Res. In press.
4. Ebbinghaus S, Rubin E, Hersch E, et al. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2005;11:7807-7816.
5. Cunningham C, Appleman LJ, Kirvan-Visovatti M, et al. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2005;11:7825-7833.
6. Mita AC, Hammond LA, Bonate PL, et al. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for three weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res. 2006;12:5207-5215.
7. Atack JR, Suman-Chauhan N, Dawson G, Kulagowski JJ. In vitro and in vivo inhibition of prolyl oligopeptidase. Eur J Pharmacol. 1991;205:157-163.
8. Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35:763-766.
9. Friedman TC, Orlowski M, Wilk S. Prolyl oligopeptidase: inhibition in vivo by N-benzyloxycarbonyl-prolyl-prolinal. J Neurochem. 1984;42:237-241.
10. Wilk S. Prolyl oligopeptidase. Life Sci. 1983;33:2149-2157.
11. Bausback HH, Ward PE. Vascular, post proline cleaving enzyme: metabolism of vasoactive peptides. Adv Exp Med Biol. 1986;198:397-404.